Skip to main content
Erschienen in: World Journal of Surgery 12/2019

12.09.2019 | Original Scientific Report

Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features

verfasst von: Tai-Chuan Kuan, Shih-Ching Chang, Jen-Kou Lin, Tzu-Chen Lin, Shung-Haur Yang, Jeng-Kae Jiang, Wei-Shone Chen, Huann-Sheng Wang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang

Erschienen in: World Journal of Surgery | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with stage II colorectal cancer (CRC) have a higher risk of recurrence when they have certain risk factors, including clinical and pathological patterns. However, as the prognostic role of molecular patterns for stage II disease is still unclear, this study aimed to investigate it.

Methods

A total of 509 patients with stage II CRC were enrolled, and all clinical, pathological, and molecular data were collected. Molecular patterns included microsatellite instability (MSI); elevated microsatellite alterations at selected tetranucleotides (EMAST) status; and expression of RAS/RAF genes, genes of the APC pathway, and other gene mutations. The endpoints were oncological outcomes, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), local recurrence (LR), and distant recurrence (DR). Cox regression analysis was used.

Results

Numerous molecular patterns influenced the oncological outcomes on univariate analysis, but no variable reached significance in LR. On multivariate analysis, a mucinous component (MC) > 50% (P < 0.01) was significant for OS and CSS. Lymphovascular invasion (LVI; P< 0.01), MC > 50% (P < 0.01), and EMAST-H (P = 0.02) significantly influenced DFS, whereas LVI (P < 0.01), MC > 50% (P < 0.01), and TP53 mutation (P = 0.02) were significant for DR.

Conclusions

In this study, MSI, EMAST, and RAS/RAF alterations did not influence the oncological outcomes. Overall, LVI and MC were two significant prognostic factors for DFS and DR. Thus, the histopathology, rather than the genes, plays a major role in the prognosis of patients with stage II CRC.
Literatur
1.
Zurück zum Zitat The Department of Health t E Y (2013) The Department of Health. Healthy statistics: Cancer Registry Annual Report in Taiwan Area, Taiwan, R.O.C The Department of Health t E Y (2013) The Department of Health. Healthy statistics: Cancer Registry Annual Report in Taiwan Area, Taiwan, R.O.C
2.
Zurück zum Zitat Dienstmann R, Vermeulen L, Guinney J et al (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79–92CrossRef Dienstmann R, Vermeulen L, Guinney J et al (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 17(2):79–92CrossRef
3.
Zurück zum Zitat Lin JK, Chang SC, Yang YC et al (2003) Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann Surg Oncol 10(9):1086–1094CrossRef Lin JK, Chang SC, Yang YC et al (2003) Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann Surg Oncol 10(9):1086–1094CrossRef
4.
Zurück zum Zitat Chang SC, Lin JK, Lin TC et al (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26(1):65–75PubMed Chang SC, Lin JK, Lin TC et al (2005) Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol 26(1):65–75PubMed
5.
Zurück zum Zitat Chang CC, Lin HH, Lin JK et al (2015) FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients. Int J Biol Markers 30(1):e88–95CrossRef Chang CC, Lin HH, Lin JK et al (2015) FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients. Int J Biol Markers 30(1):e88–95CrossRef
6.
Zurück zum Zitat Lin CC, Lin JK, Lin TC et al (2014) The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 110(4):451–457CrossRef Lin CC, Lin JK, Lin TC et al (2014) The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J Surg Oncol 110(4):451–457CrossRef
7.
Zurück zum Zitat Chang YY, Lin PC, Lin HH et al (2016) Mutation spectra of RAS gene family in colorectal cancer. Am J Surg 212(3):537–544.e533CrossRef Chang YY, Lin PC, Lin HH et al (2016) Mutation spectra of RAS gene family in colorectal cancer. Am J Surg 212(3):537–544.e533CrossRef
8.
Zurück zum Zitat Sinicrope FA, Sargent DJ (2012) Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 18(6):1506–1512CrossRef Sinicrope FA, Sargent DJ (2012) Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 18(6):1506–1512CrossRef
9.
Zurück zum Zitat Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460CrossRef Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460CrossRef
10.
Zurück zum Zitat Carethers JM (2017) Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep 13(1):73–80CrossRef Carethers JM (2017) Microsatellite instability pathway and EMAST in colorectal cancer. Curr Colorectal Cancer Rep 13(1):73–80CrossRef
11.
Zurück zum Zitat Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797–1806CrossRef Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22(10):1797–1806CrossRef
12.
Zurück zum Zitat Benson AB, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419CrossRef Benson AB, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419CrossRef
13.
Zurück zum Zitat NCCN Clinical Practice Guideline in Oncology Colon Cancer, (2017). NCCN Clinical Practice Guideline in Oncology Colon Cancer, (2017).
14.
Zurück zum Zitat Lin CC, Lai YL, Lin TC et al (2012) Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis 27(3):277–286CrossRef Lin CC, Lai YL, Lin TC et al (2012) Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis 27(3):277–286CrossRef
15.
Zurück zum Zitat Perucho M (1999) Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248–5257, 1998. Cancer Res 59(1):249–256PubMed Perucho M (1999) Correspondence re: C.R. Boland et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248–5257, 1998. Cancer Res 59(1):249–256PubMed
16.
Zurück zum Zitat Farina-Sarasqueta A, van Lijnschoten G, Moerland E et al (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21(12):2396–2402CrossRef Farina-Sarasqueta A, van Lijnschoten G, Moerland E et al (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21(12):2396–2402CrossRef
17.
Zurück zum Zitat Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 28(3):466–474CrossRef Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 28(3):466–474CrossRef
18.
Zurück zum Zitat Phipps AI, Buchanan DD, Makar KW et al (2013) KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 108(8):1757–1764CrossRef Phipps AI, Buchanan DD, Makar KW et al (2013) KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 108(8):1757–1764CrossRef
19.
Zurück zum Zitat Safaee Ardekani G, Jafarnejad SM, Tan L et al (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE 7(10):e47054CrossRef Safaee Ardekani G, Jafarnejad SM, Tan L et al (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE 7(10):e47054CrossRef
20.
Zurück zum Zitat Johnson SM, Gulhati P, Rampy BA, et al (2010) Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210(5): 767–776, 776–768.CrossRef Johnson SM, Gulhati P, Rampy BA, et al (2010) Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210(5): 767–776, 776–768.CrossRef
21.
Zurück zum Zitat Danielsen SA, Eide PW, Nesbakken A et al (2015) Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 1855(1):104–121PubMed Danielsen SA, Eide PW, Nesbakken A et al (2015) Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta 1855(1):104–121PubMed
22.
Zurück zum Zitat Bahrami A, Khazaei M, Hasanzadeh M et al (2018) Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer: rational and progress. J Cell Biochem 119(3):2460–2469CrossRef Bahrami A, Khazaei M, Hasanzadeh M et al (2018) Therapeutic potential of targeting PI3K/AKT pathway in treatment of colorectal cancer: rational and progress. J Cell Biochem 119(3):2460–2469CrossRef
23.
Zurück zum Zitat Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153–162CrossRef Vilar E, Gruber SB (2010) Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153–162CrossRef
24.
Zurück zum Zitat Carethers JM, Smith EJ, Behling CA et al (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126(2):394–401CrossRef Carethers JM, Smith EJ, Behling CA et al (2004) Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126(2):394–401CrossRef
25.
Zurück zum Zitat Devaraj B, Lee A, Cabrera BL et al (2010) Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg 14(10):1521–1528CrossRef Devaraj B, Lee A, Cabrera BL et al (2010) Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg 14(10):1521–1528CrossRef
26.
Zurück zum Zitat Garcia M, Choi C, Kim HR et al (2012) Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 143(1):48–50.e41CrossRef Garcia M, Choi C, Kim HR et al (2012) Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology 143(1):48–50.e41CrossRef
27.
Zurück zum Zitat Watson MM, Berg M, Soreide K (2014) Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer 111(5):823–827CrossRef Watson MM, Berg M, Soreide K (2014) Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer 111(5):823–827CrossRef
28.
Zurück zum Zitat Yamada K, Kanazawa S, Koike J et al (2010) Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep 23(2):551–561PubMedPubMedCentral Yamada K, Kanazawa S, Koike J et al (2010) Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan. Oncol Rep 23(2):551–561PubMedPubMedCentral
29.
Zurück zum Zitat Du W, Mah JT, Lee J et al (2004) Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 47(1):78–85CrossRef Du W, Mah JT, Lee J et al (2004) Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 47(1):78–85CrossRef
30.
Zurück zum Zitat Kang H, O'Connell JB, Maggard MA et al (2005) A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 48(6):1161–1168CrossRef Kang H, O'Connell JB, Maggard MA et al (2005) A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 48(6):1161–1168CrossRef
31.
Zurück zum Zitat Catalano V, Loupakis F, Graziano F et al (2012) Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol 23(1):135–141CrossRef Catalano V, Loupakis F, Graziano F et al (2012) Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol 23(1):135–141CrossRef
32.
Zurück zum Zitat Park JS, Huh JW, Park YA et al (2015) Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine (Baltimore) 94(15):e658CrossRef Park JS, Huh JW, Park YA et al (2015) Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine (Baltimore) 94(15):e658CrossRef
33.
Zurück zum Zitat Lim SB, Yu CS, Jang SJ et al (2010) Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum 53(4):377–384CrossRef Lim SB, Yu CS, Jang SJ et al (2010) Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum 53(4):377–384CrossRef
34.
Zurück zum Zitat Huh JW, Lee JH, Kim HR et al (2013) Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg 206(5):758–763CrossRef Huh JW, Lee JH, Kim HR et al (2013) Prognostic significance of lymphovascular or perineural invasion in patients with locally advanced colorectal cancer. Am J Surg 206(5):758–763CrossRef
35.
Zurück zum Zitat Chang S-CL, Wang H-S, Yang S-H, Jiang J-K, Lan Y-T, Lin T-C, Li F-Y, Chen W-S, Lin J-K (2012) Lymphovascular invasion determines the outcome of stage I colorectal cancer patients. Formosan Journal of Surgery 45:141–145CrossRef Chang S-CL, Wang H-S, Yang S-H, Jiang J-K, Lan Y-T, Lin T-C, Li F-Y, Chen W-S, Lin J-K (2012) Lymphovascular invasion determines the outcome of stage I colorectal cancer patients. Formosan Journal of Surgery 45:141–145CrossRef
36.
Zurück zum Zitat Nikberg M, Chabok A, Letocha H et al (2016) Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta Oncol 55(12):1418–1424CrossRef Nikberg M, Chabok A, Letocha H et al (2016) Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. Acta Oncol 55(12):1418–1424CrossRef
37.
Zurück zum Zitat Church TR, Wandell M, Lofton-Day C et al (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2):317–325CrossRef Church TR, Wandell M, Lofton-Day C et al (2014) Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2):317–325CrossRef
38.
Zurück zum Zitat Vidal J, Muinelo L, Dalmases A et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28(6):1325–1332CrossRef Vidal J, Muinelo L, Dalmases A et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28(6):1325–1332CrossRef
39.
Zurück zum Zitat Melling N, Kowitz CM, Simon R et al (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 69(3):209–214CrossRef Melling N, Kowitz CM, Simon R et al (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 69(3):209–214CrossRef
40.
Zurück zum Zitat Li P, Xiao ZT, Braciak TA et al (2016) Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer. Oncol Res Treat 39(11):696–702CrossRef Li P, Xiao ZT, Braciak TA et al (2016) Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer. Oncol Res Treat 39(11):696–702CrossRef
41.
Zurück zum Zitat Masuda T, Hayashi N, Kuroda Y, et al (2017) MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) 9(9).CrossRef Masuda T, Hayashi N, Kuroda Y, et al (2017) MicroRNAs as Biomarkers in Colorectal Cancer. Cancers (Basel) 9(9).CrossRef
42.
Zurück zum Zitat Gao S, Zhao ZY, Wu R et al (2018) Prognostic value of microRNAs in colorectal cancer: a meta-analysis. Cancer Manag Res 10:907–929CrossRef Gao S, Zhao ZY, Wu R et al (2018) Prognostic value of microRNAs in colorectal cancer: a meta-analysis. Cancer Manag Res 10:907–929CrossRef
43.
Zurück zum Zitat Rozek LS, Schmit SL, Greenson JK, et al (2016) Tumor-infiltrating lymphocytes, crohn's-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst 108(8). Rozek LS, Schmit SL, Greenson JK, et al (2016) Tumor-infiltrating lymphocytes, crohn's-like lymphoid reaction, and survival from colorectal cancer. J Natl Cancer Inst 108(8).
44.
Zurück zum Zitat Ko YS, Pyo JS (2019) Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers: 1724600818817320. Ko YS, Pyo JS (2019) Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer. Int J Biol Markers: 1724600818817320.
Metadaten
Titel
Prognosticators of Long-Term Outcomes of TNM Stage II Colorectal Cancer: Molecular Patterns or Clinicopathological Features
verfasst von
Tai-Chuan Kuan
Shih-Ching Chang
Jen-Kou Lin
Tzu-Chen Lin
Shung-Haur Yang
Jeng-Kae Jiang
Wei-Shone Chen
Huann-Sheng Wang
Yuan-Tzu Lan
Chun-Chi Lin
Hung-Hsin Lin
Sheng-Chieh Huang
Publikationsdatum
12.09.2019
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 12/2019
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05158-w

Weitere Artikel der Ausgabe 12/2019

World Journal of Surgery 12/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.